Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc.
180 North LaSalle Street
Suite 1600
Chicago, IL 60601
United States
844 445 5704
https://www.xerispharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 377
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Paul R. Edick | Chairman & CEO | 1.21M | N/D | 1956 |
| Mr. John P. Shannon | President & COO | 918.15k | N/D | 1962 |
| Mr. Steven M. Pieper | Chief Financial Officer | 681.14k | N/D | 1978 |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 695.44k | N/D | 1964 |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior VP of Global Development & Medical Affairs | 596.97k | N/D | 1963 |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Kevin McCulloch | Chief Commercial Officer | N/D | N/D | N/D |
Descripción
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Gestión corporativa
La calificación ISS Governance QuickScore de Xeris Biopharma Holdings, Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 8; Compensación: 10.
